LAST SEPTEMBER, the diet drugs fenfluramine and dexfenfluramine were
withdrawn after the Food and Drug Administration (FDA) reviewed echocardiographic
studies indicating heart valve abnormalities in 31% of the patients tested.1 While the FDA acted within days of receiving the heart
valve data, fenfluramine had been approved 24 years earlier.2
In December 1997, the popular nonsedating antihistamine terfenadine was withdrawn
because a safer alternative existed without terfenadine's risk of potentially
lethal cardiac arrhythmia.3 Terfenadine had
been on the market for 12 years.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 61
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.